<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 3; Issue 1</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Jan-Feb, 2022)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>A Dual-Cancer Patient with Disease-Free Survival for 63 Months and Over 70 Cycles of Alimta: A Case Report</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>3</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Min</FirstName>
          <LastName>Zhang</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Huan Zhou</FirstName>
          <LastName/>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Dan</FirstName>
          <LastName>Liu</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Jun</FirstName>
          <LastName>Chen</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>Of all malignant tumors, lung cancer has the highest mortality rate. Here, a rare case of a dual-cancer patient with stage IVA non-Hodgkin__ampersandsign#39;s lymphoma and stage IIA lung adenocarcinoma has been reported. The patient received more than 70 cycles of Alimta without any adverse reactions caused by chemotherapy, and his disease-free survival reached 63 months.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Non-Hodgkin’s Lymphoma,Lung Adenocarcinoma,Disease-Free Survival,Alimta</Keywords>
      <URLs>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13560&amp;title=A Dual-Cancer Patient with Disease-Free Survival for 63 Months and Over 70 Cycles of Alimta: A Case Report</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Dietrich J, Versmee L, Drappatz J, Eichler AF, Nayak L, Norden A, Wong E, Pisapia MR, Jones SS, Gordon AB, Chabner BA. Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. Oncologist 2020; 25: 747-e1273.&#13;
&#13;
Freedman A and Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 2020; 95: 316-327.&#13;
&#13;
Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.&#13;
&#13;
Zhang L, Ou W, Liu Q, Li N, Liu L, Wang S. Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer. Thorac Cancer 2014; 5: 50-56.&#13;
&#13;
Zuo S, Wei M, Zhang H, Chen A, Wu J, Wei J, Dong J. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer. J Transl Med 2019; 17: 1-6.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>